<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582086</url>
  </required_header>
  <id_info>
    <org_study_id>15E-0601</org_study_id>
    <nct_id>NCT02582086</nct_id>
  </id_info>
  <brief_title>Study of a New Topical Natural Health Product for the Treatment of Herpes Labialis</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Topical Natural Health Product for the Treatment of Herpes Labialis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire Boreaderme Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire Boreaderme Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the safety and efficacy of a topical natural health
      product in comparison to placebo for the treatment of herpes labialis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to healing as assessed by the investigator</measure>
    <time_frame>up to 10 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Herpes Labialis</condition>
  <arm_group>
    <arm_group_label>BOR15001L7 Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BOR15001L7 Cream with 5% 15019L0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BOR15001L7</intervention_name>
    <description>Active cream with 5% 15019L0</description>
    <arm_group_label>BOR15001L7 Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Cream with 0% 15019L0</description>
    <arm_group_label>Placebo Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male, in good health, 18 years of age or older,

          -  With history of recurrent herpes labialis with at least twice a year during the past
             twenty-four months,

          -  Agreeing not to take another treatment against cold sore, nor anti-inflammatory,
             antibiotics and steroids,

          -  Cooperating in the study, able to be monitored at each visit, aware of the demands and
             duration of the controls, thus allowing perfect adherence to the established protocol,

          -  Must be willing and able to participate and to provide written informed consent,

          -  Female subjects of childbearing potential must have a negative pregnancy test at
             screening and agree to use a proper contraceptive method during the study.

        Exclusion Criteria:

          -  Volunteers who refuse to introduce the product to be tested in its routine,

          -  With a history of hypersensitivity to the type of product to be tested (e.g., products
             that contain essential oil),

          -  Who have a history of eczema, topical dermatitis, psoriasis or significant skin
             anomalies on the areas to be tested,

          -  Who suffer from a serious illness or health problem or a critical or progressive
             disease,

          -  Who have taken prescription or over the counter medication that could affect skin
             characteristics or could bias the study (i.e. antibiotics, antihistamines,
             anti-inflammatories…) within 7 days prior to study beginning,

          -  Who have recently acquired or who currently have significant skin pigmentation, who
             frequent tanning salons or foresee exposure to the sun during the study,

          -  Who abuse alcohol, drugs and/or tobacco,

          -  Female subjects who are pregnant, breastfeeding or expecting to become pregnant during
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elisabeth EF Fiquet, M. Sc</last_name>
    <phone>5143430001</phone>
    <phone_ext>206</phone_ext>
    <email>efiquet@evalulab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Evalulab Inc</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4P 1P7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth EF Fiquet, M. Sc.</last_name>
      <phone>5143430001</phone>
      <phone_ext>206</phone_ext>
      <email>efiquet@evalulab.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Labialis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

